Ralf Kuriyel (SVP R&D) sold 7,148 shares at $159.35 avg; post-sale holdings 12,288 shares (-36.8%)
Ralf Kuriyel, Senior VP of R&D at Repligen, executed 2 separate sales totaling 7,148 shares for $1,139,016.03 on August 2, 2024, reducing his holdings by 36.8% to 12,288 shares. The sales occurred at a blended average price of $159.35, near the current price of $162.20 and within the 52-week trading range. Repligen's financial backdrop shows annual revenue declined 20.3% year-over-year to $154,073,000.00 in the latest quarter, with net income at $3,321,000.00 and a notably elevated P/E of 216.27, reflecting a market cap of $9,084,253,975.60. The sale represents a material reduction in an R&D executive's equity stake during a period of significant revenue contraction, though without scheduled trade plan disclosure or prior trade history context, the transaction's strategic intent cannot be determined from the filing alone.